Is Gardasil 9 (human papillomavirus vaccine) recommended for a healthy 30‑year‑old woman who has not completed the HPV series, and what are the dosing schedule and contraindications?

HPV Vaccination for a 30-Year-Old Woman

A healthy 30-year-old woman who has not completed the HPV vaccine series should receive Gardasil 9 using a 3-dose schedule (0,1–2, and 6 months) to protect against HPV-related cancers and genital warts, even if she is sexually active. 1, 2

Eligibility and FDA Approval

• Gardasil 9 is FDA-approved for women aged 9 through 26 years, and the FDA extended approval in October 2018 for adults aged 27–45 years. 1, 2
• Catch-up vaccination is recommended for all persons through age 26 years who are not adequately vaccinated, making your 30-year-old patient eligible under the extended age indication. 1
• For adults aged 27–45 years, the CDC recommends shared clinical decision-making rather than universal vaccination, but factors favoring vaccination include new or anticipated sexual partners, limited lifetime sexual partners, or immunocompromising conditions. 1

Dosing Schedule

Because this patient is 30 years old, she requires the 3-dose schedule:

• Dose 1: Day 0
• Dose 2: 1–2 months after the first dose (minimum interval 4 weeks)
• Dose 3: 6 months after the first dose (minimum interval 12 weeks after dose 2) 1, 3, 2

The 2-dose schedule is only for individuals who initiate vaccination before their 15th birthday; anyone starting at age 15 or older requires three doses. 1, 3

Administration Details

• Administer 0.5 mL intramuscularly into the deltoid muscle of the upper arm or the anterolateral thigh. 2
• Shake the vial or syringe well immediately before administration to maintain suspension. 2
• Observe the patient for 15 minutes after injection due to the risk of syncope, which can occur in adults as well as adolescents. 3, 2

Pre-Vaccination Testing

No laboratory or clinical testing is required before administering the HPV vaccine:

• No Pap smear, HPV DNA test, or HPV antibody test is needed. 1
• A history of genital warts, abnormal Pap results, or a positive HPV test is not a contraindication to vaccination. 1

Rationale for Vaccination in Sexually Active Adults

• Even sexually active women should be vaccinated because they are unlikely to have been infected with all nine HPV types covered by Gardasil 9 (types 6,11,16,18,31,33,45,52,58). 1, 4
• The vaccine does not protect against HPV types a person is already infected with at the time of vaccination, but it will protect against other vaccine HPV types not yet acquired. 5, 1
• Although overall vaccine effectiveness is lower in older, sexually active populations compared to pre-exposure vaccination, the majority of women in this age group will derive at least partial benefit. 5

Contraindications

The only absolute contraindication is:

• Severe allergic reaction (anaphylaxis) to yeast (a vaccine component) or after a previous dose of Gardasil 9 or Gardasil. 2

Pregnancy-related guidance:

• Vaccination is not recommended during pregnancy; if pregnancy occurs during the series, postpone subsequent doses until after delivery. 1
• Pregnancy testing is not required before vaccination. 1
• Breastfeeding is not a contraindication—lactating women may receive the vaccine. 1

Interrupted Series Management

• If the vaccination series is interrupted, do not restart the series—continue from where you left off. 1, 3
• The critical factor is the age at the first dose, not when subsequent doses are given. 1
• Ensure minimum intervals are met: 4 weeks between doses 1 and 2, and 12 weeks between doses 2 and 3. 1, 3

Cancer Prevention Benefits

• Gardasil 9 prevents approximately 90% of cervical cancers (types 16,18,31,33,45,52,58), 90% of anal cancers, 70% of oropharyngeal cancers, and 60–70% of vaginal, vulvar, and penile cancers. 1
• It also prevents approximately 90% of genital warts caused by HPV types 6 and 11. 1, 4
• Compared to the older quadrivalent vaccine, Gardasil 9 prevents an additional 14% of anogenital cancers and up to 30% of high-risk precancerous cervical lesions. 1, 6

Cervical Cancer Screening

Cervical cancer screening must continue regardless of vaccination status:

• The vaccine does not protect against all oncogenic HPV types, so routine screening per standard guidelines remains essential. 1, 2
• Vaccination does not eliminate the need for Pap smears or HPV testing. 5, 1

Common Pitfalls to Avoid

• Do not delay vaccination waiting for "optimal" timing or test results—administer as soon as the patient is eligible. 1
• Do not withhold vaccination from sexually active women; they remain at risk for HPV types not yet acquired. 5, 1
• Do not restart the series if interrupted—simply continue with the next dose maintaining minimum intervals. 1, 3
• Do not skip cervical cancer screening in vaccinated women—screening remains mandatory. 1, 2